Population pharmacokinetic (PK) and exposure-response analyses from the pivotal ALTA-1L study: Model-based analyses supporting the brigatinib dose in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC).

Neeraj Gupta,Karen L. Reckamp,D. Ross Camidge,Huub Jan Kleijn,Aziz Ouerdani,Francesco Bellanti,John Maringwa,Michael J. Hanley,Shining Wang,Pingkuan Zhang, Karthik Venkatakrishnan

Journal of Clinical Oncology（2020）

Cited 2|Views8

No score

Abstract

e21725Background: Brigatinib is a next-generation ALK tyrosine kinase inhibitor (TKI) with differential activity by dose (90 mg vs 180 mg [with a 7-day lead-in at 90 mg] qd) in the phase 2 post-cri...

Translated text

Key words

Anaplastic lymphoma kinase,Brigatinib,non-small cell lung cancer (NSCLC),Tyrosine-kinase inhibitor,Population,Cancer research,Pharmacokinetics,Medicine,ALK-Positive,Exposure response

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined